Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Coronaviruses pose a serious threat to global health as evidenced by Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and COVID-19. SARS Coronavirus (SARS-CoV), MERS Coronavirus (MERS-CoV), and the novel coronavirus, previously dubbed 2019-nCoV, and now officially named SARS-CoV-2, are the causative agents of the SARS, MERS, and COVID-19 disease outbreaks, respectively. Safe vaccines that rapidly induce potent and long-lasting virus-specific immune responses against these infectious agents are urgently needed. The coronavirus spike (S) protein, a characteristic structural component of the viral envelope, is considered a key target for vaccines for the prevention of coronavirus infection. METHODS: We first generated codon optimized MERS-S1 subunit vaccines fused with a foldon trimerization domain to mimic the native viral structure. In variant constructs, we engineered immune stimulants (RS09 or flagellin, as TLR4 or TLR5 agonists, respectively) into this trimeric design. We comprehensively tested the pre-clinical immunogenicity of MERS-CoV vaccines in mice when delivered subcutaneously by traditional needle injection, or intracutaneously by dissolving microneedle arrays (MNAs) by evaluating virus specific IgG antibodies in the serum of vaccinated mice by ELISA and using virus neutralization assays. Driven by the urgent need for COVID-19 vaccines, we utilized this strategy to rapidly develop MNA SARS-CoV-2 subunit vaccines and tested their pre-clinical immunogenicity in vivo by exploiting our substantial experience with MNA MERS-CoV vaccines. FINDINGS: Here we describe the development of MNA delivered MERS-CoV vaccines and their pre-clinical immunogenicity. Specifically, MNA delivered MERS-S1 subunit vaccines elicited strong and long-lasting antigen-specific antibody responses. Building on our ongoing efforts to develop MERS-CoV vaccines, promising immunogenicity of MNA-delivered MERS-CoV vaccines, and our experience with MNA fabrication and delivery, including clinical trials, we rapidly designed and produced clinically-translatable MNA SARS-CoV-2 subunit vaccines within 4 weeks of the identification of the SARS-CoV-2 S1 sequence. Most importantly, these MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses that were evident beginning 2 weeks after immunization. INTERPRETATION: MNA delivery of coronaviruses-S1 subunit vaccines is a promising immunization strategy against coronavirus infection. Progressive scientific and technological efforts enable quicker responses to emerging pandemics. Our ongoing efforts to develop MNA-MERS-S1 subunit vaccines enabled us to rapidly design and produce MNA SARS-CoV-2 subunit vaccines capable of inducing potent virus-specific antibody responses. Collectively, our results support the clinical development of MNA delivered recombinant protein subunit vaccines against SARS, MERS, COVID-19, and other emerging infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Prausnitz, M. R., & Langer, R. (2008) · Nature Biotechnology · doi:10.1038/nbt.1504 · Cited by 3,517
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 1×
“[7-11] Due to this vital functional property and established antigenicity, the S protein is an important target for vaccine development.”
Self-citationDissolving microneedles for transdermal drug delivery
Lee, J. W., Park, J.-H., & Prausnitz, M. R. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.048 · Cited by 968
Dissolving polymer microneedle patches for influenza vaccination
Sullivan, S. P., Koutsonanos, D. G., del Pilar Martin, M., Lee, J. W., Zarnitsyn, V., Choi, S.-O., Murthy, N., Compans, R. W., Skountzou, I., & Prausnitz, M. R. (2010) · Nature Medicine · doi:10.1038/nm.2182 · Cited by 948
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Construction of adenovirus vectors through Cre-lox recombination
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., & Phipps, M. L. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1842-1849.1997 · Cited by 789
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., et al. (2013) · Nature · doi:10.1038/nature12328 · Cited by 739
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X., et al. (2013) · Cell Research · doi:10.1038/cr.2013.92 · Cited by 719
The immunological anatomy of the skin
Kabashima, K., Honda, T., Ginhoux, F., & Egawa, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0084-5 · Cited by 650 · cited 1×
“It contains a rich population of antigen presenting and immune accessory cells capable of inducing a proinflammatory microenvironment favoring the induction of potent and durable adaptive immunity [24,25].”
Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., & Wang, X. (2017) · Cell Research · doi:10.1038/cr.2016.152 · Cited by 589
Rouphael, N. G., Paine, M., Mosley, R., Henry, S., McAllister, D. V., Kalluri, H., Pewin, W., Frew, P. M., Yu, T., Thornburg, N. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30575-5 · Cited by 442
Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin
Prausnitz, M. R. (2017) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060816-101514 · Cited by 439
Current advances in the fabrication of microneedles for transdermal delivery
Indermun, S., Luttge, R., Choonara, Y. E., Kumar, P., du Toit, L. C., Modi, G., & Pillay, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.052 · Cited by 399
Antigen-Presenting Cells in the Skin
Kashem, S. W., Haniffa, M., & Kaplan, D. H. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052215 · Cited by 361
Microneedle patches: Usability and acceptability for self-vaccination against influenza
Norman, J. J., Arya, J. M., McClain, M. A., Frew, P. M., Meltzer, M. I., & Prausnitz, M. R. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.01.076 · Cited by 281
Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R., & Sodroski, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4634-4642.2002 · Cited by 277
Gao, W., Soloff, A. C., Lu, X., Montecalvo, A., Nguyen, D. C., Matsuoka, Y., Robbins, P. D., Swayne, D. E., Donis, R. O., Katz, J. M., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1959-1964.2006 · Cited by 270
Self-citationTao, Y., Strelkov, S. V., Mesyanzhinov, V. V., & Rossmann, M. G. (1997) · Structure · doi:10.1016/s0969-2126(97)00233-5 · Cited by 227
Microneedle patches for vaccination in developing countries
Arya, J., & Prausnitz, M. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.019 · Cited by 224
Pascal, K. E., Coleman, C. M., Mujica, A. O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510830112 · Cited by 217
Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination
Boopathy, A. V., Mandal, A., Kulp, D. W., Menis, S., Bennett, N. R., Watkins, H. C., Wang, W., Martin, J. T., Thai, N. T., He, Y., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902179116 · Cited by 198
Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
Shanmugam, A., Rajoria, S., George, A. L., Mittelman, A., Suriano, R., & Tiwari, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030839 · Cited by 180
Krammer, F., Margine, I., Tan, G. S., Pica, N., Krause, J. C., & Palese, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043603 · Cited by 173
Hexahistidine (His6)-tag dependent protein dimerization: a cautionary tale.
Wu, J., & Filutowicz, M. (1999) · Acta Biochimica Polonica · doi:10.18388/abp.1999_4131 · Cited by 163
Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination
Balmert, S. C., Carey, C. D., Falo, G. D., Sethi, S. K., Erdös, G., Korkmaz, E., & Falo, L. D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.023 · Cited by 154
Self-citationDissolvable Microneedle Arrays for Intradermal Delivery of Biologics: Fabrication and Application
Bediz, B., Korkmaz, E., Khilwani, R., Carey, C. D., Erdös, G., Falo, L. D., & Özdoğanlar, O. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1137-x · Cited by 151
Self-citationOrganization of the skin immune system and compartmentalized immune responses in infectious diseases
Quaresma, J. A. S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-18 · Cited by 149
Fernando, G. J. P., Hickling, J., Flores, C. M. J., Griffin, P., Anderson, C. D., Skinner, S. R., Davies, C., Witham, K. L., Pryor, M. J., Bodle, J., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.053 · Cited by 137
Kim, E., Okada, K., Kenniston, T., Raj, V. S., AlHajri, M. M., Farag, E. A. B. A., AlHajri, F., Osterhaus, A. D. M. E., Haagmans, B. L., & Gambotto, A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.08.058 · Cited by 135
Self-citationSong, H. C., Seo, M.-Y., Stadler, K., Yoo, B. J., Choo, Q.-L., Coates, S. R., Uematsu, Y., Harada, T., Greer, C. E., Polo, J. M., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10328-10335.2004 · Cited by 135
Chen, Y., Rajashankar, K. R., Yang, Y., Agnihothram, S. S., Liu, C., Lin, Y.-L., Baric, R. S., & Li, F. (2013) · Journal of Virology · doi:10.1128/jvi.01756-13 · Cited by 134
Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation
Kim, E., Erdös, G., Huang, S., Kenniston, T. W., Falo, L. D., & Gambotto, A. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.028 · Cited by 124
Self-citationMERS coronavirus outbreak: Implications for emerging viral infections
Al-Omari, A., Rabaan, A. A., Salih, S., Al-Tawfiq, J. A., & Memish, Z. A. (2019) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.10.011 · Cited by 122
Skountzou, I., Martin, M. D. P., Wang, B., Ye, L., Koutsonanos, D., Weldon, W., Jacob, J., & Compans, R. W. (2010) · Vaccine · doi:10.1016/j.vaccine.2009.07.058 · Cited by 121
Al-Kasasbeh, R., Brady, A. J., Courtenay, A. J., Larrañeta, E., McCrudden, M., O’Kane, D., Liggett, S. B., & Donnelly, R. F. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00727-2 · Cited by 118
Quan, F., Kim, Y., Compans, R. W., Prausnitz, M. R., & Kang, S. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.125 · Cited by 117
Widjaja, I., Wang, C., van Haperen, R., Gutiérrez-Álvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1597644 · Cited by 115
Self-citationTai, W., Zhao, G., Sun, S., Guo, Y., Wang, Y., Tao, X., Tseng, C.-T. K., Li, F., Jiang, S., Du, L., et al. (2016) · Virology · doi:10.1016/j.virol.2016.10.005 · Cited by 109
CD4+ T Cell Responses Elicited by Different Subsets of Human Skin Migratory Dendritic Cells
Morelli, A. E., Rubin, J. P., Erdos, G., Tkacheva, O. A., Mathers, A. R., Zahorchak, A. F., Thomson, A. W., Falo, L. D., & Larregina, A. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.7905 · Cited by 108
Self-citationKorkmaz, E., Friedrich, E. E., Ramadan, M. H., Erdös, G., Mathers, A. R., Özdoğanlar, O. B., Washburn, N. R., & Falo, L. D. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.05.036 · Cited by 107
Self-citationPark, H. Y., Lee, E. J., Ryu, Y. W., Kim, Y., Kim, H., Lee, H., & Yi, S. (2015) · Eurosurveillance · doi:10.2807/1560-7917.es2015.20.25.21169 · Cited by 102
Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches
Chu, L. Y., Ye, L., Dong, K., Compans, R. W., Yang, C., & Prausnitz, M. R. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1833-9 · Cited by 99
Colocalization of Cell Death with Antigen Deposition in Skin Enhances Vaccine Immunogenicity
Depelsenaire, A. C. I., Meliga, S. C., McNeilly, C. L., Pearson, F. E., Coffey, J. W., Haigh, O. L., Flaim, C. J., Frazer, I. H., & Kendall, M. A. F. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.174 · Cited by 98
Bachy, V. S., Hervouet, C., Becker, P. D., Chorro, L., Carlin, L. M., Herath, S., Papagatsias, T., Barbaroux, J.-B., Oh, S., Benlahrech, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214449110 · Cited by 97
Transdermal immunomodulation: Principles, advances and perspectives
Zhao, Z., Ukidve, A., Dasgupta, A., & Mitragotri, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.010 · Cited by 92
Li, J., Ulitzky, L., Silberstein, E., Taylor, D. R., & Viscidi, R. P. (2013) · Viral Immunology · doi:10.1089/vim.2012.0076 · Cited by 89
Professional antigen-presenting cells of the skin
Mathers, A. R., & Larregina, A. T. (2006) · Immunologic Research · doi:10.1385/ir:36:1:127 · Cited by 87
Hegde, N. R., Kaveri, S. V., & Bayry, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.07.004 · Cited by 86
Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
Stalin Raj, V., Okba, N. M. A., Gutierrez-Alvarez, J., Drabek, D., van Dieren, B., Widagdo, W., Lamers, M. M., Widjaja, I., Fernandez-Delgado, R., Sola, I., et al. (2018) · Science Advances · doi:10.1126/sciadv.aas9667 · Cited by 84
Self-citationOkba, N. M. A., Raj, V. S., Widjaja, I., GeurtsvanKessel, C. H., de Bruin, E., Chandler, F. D., Park, W. B., Kim, N.-J., Farag, E. A. B. A., Al-Hajri, M., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2510.190051 · Cited by 79
Self-citationZhao, J., Perera, R. A. P. M., Kayali, G., Meyerholz, D., Perlman, S., & Peiris, M. (2015) · Journal of Virology · doi:10.1128/jvi.00446-15 · Cited by 68 · cited 1×
“…others have shown effective protection against MERS-CoV challenge in hDPP4-expressing mice at comparable or lower neutralizing titers in previous passive immunotherapy studies with MERS-CoV-speci fi c antibodies or neutralizing sera obtained from MERS-CoV immune humans or animals [50 (cid:1) 53].”
Cutaneous immune responses mediated by dendritic cells and mast cells
Sumpter, T. L., Balmert, S. C., & Kaplan, D. H. (2019) · JCI Insight · doi:10.1172/jci.insight.123947 · Cited by 67
Self-citationKorkmaz, E., Friedrich, E. E., Ramadan, M. H., Erdös, G., Mathers, A. R., Özdoğanlar, O. B., Washburn, N. R., & Falo, L. D. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.07.008 · Cited by 54
Self-citationSong, L., Xiong, D., Kang, X., Yang, Y., Wang, J., Guo, Y., Xu, H., Chen, S., Peng, D., Pan, Z., et al. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0195-z · Cited by 48
Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes
Zhao, X. Y., Birchall, J. C., Coulman, S. A., Tatović, D., Singh, R., Li, W., Wong, F. S., Dayan, C. M., & Hanna, S. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.040 · Cited by 48
Nishiura, H., Endo, A., Saitoh, M., Kinoshita, R., Ueno, R., Nakaoka, S., Miyamatsu, Y., Dong, Y., Chowell, G., & Mizumoto, K. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009936 · Cited by 42
Foldon‐guided self‐assembly of ultra‐stable protein fibers
Bhardwaj, A., Walker‐Kopp, N., Wilkens, S., & Cingolani, G. (2008) · Protein Science · doi:10.1110/ps.036111.108 · Cited by 34
Neuronal Regulation of Cutaneous Immunity
Cohen, J. A., Wu, J., & Kaplan, D. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901109 · Cited by 33
Bordetella bronchisepticaFlagellin Is a Proinflammatory Determinant for Airway Epithelial Cells
López-Boado, Y. S., Cobb, L. M., & Deora, R. (2005) · Infection and Immunity · doi:10.1128/iai.73.11.7525-7534.2005 · Cited by 32
His-Tag-Mediated Dimerization of Chemoreceptors Leads to Assembly of Functional Nanoarrays
Haglin, E. R., Yang, W. J., Briegel, A., & Thompson, L. K. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00698 · Cited by 24
Yu, F., Ye, L., Guo, Y., Wang, L., Yang, J. W., Zhao, G., Zhou, Y., Du, L., & Jiang, S. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1074363 · Cited by 14
Cited by
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Ciotti, M., Ciccozzi, M., Terrinoni, A., Jiang, W.-C., Wang, C.-B., & Bernardini, S. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1783198 · Cited by 1,514
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults
Fisher, K. A., Bloomstone, S. J., Walder, J., Crawford, S., Fouayzi, H., & Mazor, K. M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3569 · Cited by 1,189
Chamola, V., Hassija, V., Gupta, V., & Guizani, M. (2020) · IEEE Access · doi:10.1109/access.2020.2992341 · Cited by 1,099
“Pending FDA’s approval, phase I of the clinical trials for this vaccine are slated to commence soon [91].”
Background
Metadata
- Authors
- Kim, E., Erdos, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., Raj, V. S., Epperly, M. W., Klimstra, W. B., Haagmans, B. L., Korkmaz, E., Falo, L. D., & Gambotto, A.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 55
- Pages
- 102743
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W3013541100
- Cited by
- 404
- References
- 62
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.